Anti-factor Xa is a test that monitors the effect of applied anticoagulant therapy, depending on the anticoagulant used – low molecular weight heparins (LMWH), ultra-fractionated heparins (UFH) or direct oral anticoagulants.

Heparin is an anticoagulant – a drug that inhibits blood clotting.

Eliquis (medicinal product) contains the active substance apixaban. Apixaban is a potent oral, reversible, direct and highly selective inhibitor of the active site of factor Xa. It is used in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation with one or more risk factors, such as previous stroke or transient ischemic attack (TIA), hypertension, diabetes mellitus and symptomatic heart failure. * Eliquis contains lactose

Treatment of the individual patient should be evaluated regularly by weighing the risk of ischemic events against the risk of bleeding. A decision to continue treatment should be made by a specialist, based on the individual patient’s condition.